Bpifrance

Objow is a platform developed by Fire Tiger, a company established in 2018 and based in Lyon, France. The platform aims to enhance employee engagement and performance by centralizing performance data and enabling businesses to set personalized goals. It incorporates gamification elements to motivate teams, converting performance achievements into rewards that stimulate involvement in reaching objectives. Objow is part of Fire Tiger's broader focus on providing innovative internet-based solutions that improve sales team productivity through effective strategies and tools. With pricing starting from €9.00 per month, Objow caters to organizations seeking to boost employee performance and engagement.

MaaT Pharma is a clinical-stage biotechnology company based in Lyon, France, founded in 2014. It specializes in developing therapies aimed at treating diseases associated with gut microbiota imbalance, particularly in the context of cancer and Graft-versus-Host Disease, a complication related to stem cell transplantation. The company has made significant advancements in its research, achieving proof of concept in patients with acute myeloid leukemia. MaaT Pharma employs a comprehensive approach to restore microbiome symbiosis, which has implications for enhancing survival outcomes in life-threatening conditions. Additionally, it has developed a proprietary platform called GutPrint®, which is instrumental in evaluating drug candidates and identifying biomarkers for microbiome-related diseases, thereby supporting the expansion of its therapeutic pipeline, including improvements in immunotherapy for solid tumors.

Langa International is an independent energy producer based in Lyon, France, specializing in the development, construction, and operation of renewable energy facilities. The company focuses on a diverse range of renewable energy solutions, including solar, wind, hydroelectricity, energy storage, and green hydrogen. By imagining, designing, and deploying innovative and competitive energy solutions, Langa International enables the realization of projects worldwide, contributing to the global transition towards sustainable energy sources.

B2ebike, established in 2016 and headquartered in Lyon, France, specializes in manufacturing electric bikes. Its product portfolio comprises the B2 city range and B2 boost range. The company focuses on providing comprehensive electric bicycle fleet solutions for businesses and communities, promoting a shift towards sustainable, soft transportation. B2ebike offers mobility plans to real estate developers, enabling clients to adopt electrically assisted bicycles with dedicated terminals and applications, thereby enhancing performance and well-being.

Mon Petit Placement, founded in 2017 and based in Lyon, France, is a company that develops an online financial platform focused on enhancing the saving habits of young people. The platform serves as an intermediary between portfolio management firms and banking institutions, offering users a personalized investment strategy through an intuitive and engaging interface. This allows young investors to make informed investment decisions and effectively improve their savings practices.

Rushmix SAS, founded in 2018 and based in Lyon, France, operates a platform that enables users to transform their videos and pictures into short films within 72 hours. The service caters to a variety of needs, offering options for sports films, wedding films, family films, travel movies, and custom projects. Rushmix aims to simplify the video editing process for consumers and businesses, allowing them to create engaging visual content that enhances their digital communication and effectively conveys their messages.

1Kubator is an innovation network that supports start-up companies through various initiatives aimed at fostering entrepreneurship. The company provides training, incubation programs, acceleration programs, and open innovation offerings across several French cities, including Lyon, Bordeaux, Nantes, Rennes, Lille, and Strasbourg. By focusing on empowering young entrepreneurs, 1Kubator aims to facilitate the growth and development of start-ups, helping them achieve their potential in a competitive market.

B-Hive Engineering is an engineering and operational consulting firm based in Mulhouse, France, with additional offices in Lyon and Paris, and operations in Montréal, Canada. Founded in 2017, the company specializes in providing technical assistance and project management services across various sectors, including chemistry, petrochemistry, energy, food, pharmaceuticals, biotechnology, automotive, rail, aeronautics, and civil engineering. B-Hive Engineering supports clients throughout the study and design phases of projects, offering operational support and training in project management to effectively address project challenges. The firm is dedicated to enhancing efficiency in industry, transport, and construction sectors.

Fab'entech, founded in 2009 in Lyon, France, is a biopharmaceutical company that specializes in developing and commercializing innovative passive immunotherapeutic solutions. The company focuses on specific polyclonal immunoglobulins [F(ab’)₂] to address emerging infectious diseases and certain drug intoxications. By utilizing highly purified fragments of horse-specific polyclonal immunoglobulins, Fab'entech provides healthcare institutions with effective treatments for emergency situations. As a member of the LyonBiopôle cluster, the company is positioned within a network that fosters biotechnological advancements in the region.

Laclarée Vision specializes in the development of adaptive eyeglasses designed to correct presbyopia. Founded in 2016 and based in Lyon, France, the company utilizes patented fluid technology to create lenses that automatically adjust in real-time to various viewing distances. This innovative approach addresses the needs of individuals aged 45 and older who often find traditional solutions, such as progressive lenses or multiple pairs of glasses, unsatisfactory. By combining adaptive lens technology with refractive correction for conditions like astigmatism, myopia, and hyperopia, Laclarée aims to provide a clearer vision experience for its users.

FinKey is a financing advisory firm founded in 2017 and based in Lyon, France. Specializing in mergers and acquisitions, FinKey assists small and medium-sized businesses in identifying suitable investment banks and investors for their financing needs. The firm offers advisory services for various transactions, including mergers, acquisitions, and leveraged buyouts. It primarily serves clients in sectors such as information technology, software, cloud technology, and software as a service (SaaS), providing tailored support to help businesses navigate complex financial landscapes.

ADDEV Materials SAS, founded in 2006 and based in Lyon, France, specializes in the manufacturing and distribution of high-performance materials, including adhesive tapes, glues, mastics, abrasives, insulation, and technical components. The company serves a variety of industries, such as automotive, aerospace, energy, railway, nuclear, and medical, by transforming and custom cutting various types of insulation and technical films. Additionally, ADDEV Materials provides customized solutions and distribution services for technical adhesives, helping clients address their specific technical challenges effectively.

ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, that focuses on the discovery and development of innovative treatments for acute and chronic viral infections. Established in 2014 by a team of scientists from the Infectiology Research Center, the company utilizes a proprietary platform to identify intracellular therapeutic targets and develop small molecule therapeutics. ENYO Pharma's research primarily targets significant human infecting viruses, with current programs aimed at treating chronic hepatitis B and severe influenza. The company's pipeline includes a lead compound, EYP001, which modulates FXR to reduce the cccDNA reservoir and inhibit the expression of viral proteins, along with EYP002, which is in preclinical studies. With an emphasis on addressing unmet medical needs in infectious diseases and metabolic disorders, ENYO Pharma has established collaborations with prominent research institutions to enhance its drug development efforts.

Fill Up Média is a French advertising agency that specializes in installing advertising screens at fuel dispensing pumps. Founded in 2011 and based in Lyon, the company offers a unique communication medium that enables the display of multimedia advertising content during the fueling process. With a network of approximately 4,400 screens across more than 630 gas stations in France, Fill Up Média serves as a significant player in external communication within the industry. The screens provide a platform for targeted and engaging advertising, enriching the customer experience while they refuel.

Wizaplace is a software as a service (SaaS) platform based in Lyon, France, that specializes in the creation and management of various types of marketplaces, including B2C, B2B, and C2C projects, as well as tailored service marketplaces. Founded in 2012, the platform provides an all-in-one solution that integrates essential functions for building and managing marketplaces in a single environment. It features a comprehensive back office for administrators and sellers, alongside a user-friendly front office for clients. Wizaplace aims to democratize the marketplace model by offering customizable options, allowing e-retailers to efficiently develop their e-commerce platforms with ease.

Poxel S.A. is a biopharmaceutical company based in Lyon, France, focused on developing innovative treatments for metabolic diseases, primarily type 2 diabetes and non-alcoholic steatohepatitis (NASH). Founded in 2009 as a spin-off from Merck Serono, Poxel is advancing its lead product, Imeglimin, through Phase III clinical trials; this oral anti-diabetic candidate targets organ functions affected by diabetes, such as the pancreas, liver, and muscles. The company is also developing PXL770, currently in Phase IIa trials, which activates the adenosine monophosphate-activated protein kinase (AMPK) to manage energy metabolism, and PXL065, a mitochondrial pyruvate carrier inhibitor in Phase I trials for NASH. Additionally, Poxel has a licensing agreement with Enyo Pharma for the development of PXL007, an FXR agonist in Phase I studies for hepatitis B and NASH. The company’s pipeline reflects its commitment to addressing critical targets in cellular energy regulation, which are vital for treating metabolic disorders.